Extended-release naltrexone versus standard oral naltrexone versus placebo for opioid use disorder: the NEAT three-arm RCT

John Strang,1* Michael Kelleher,2 Soraya Mayet,3 Ed Day,1 Jennifer Hellier,4 Sarah Byford,5 Caroline Murphy,6 Blair McLennan,6 James Shearer,5 Elizabeth Ryan4 and John Marsden1

1National Addiction Centre, Institute of Psychiatry, Psychology & Neuroscience, King’s College London, London, UK
2South London and Maudsley NHS Foundation Trust, Lambeth Addictions Consortium, London, UK
3Specialist Care Group (Addictions), Humber NHS Foundation Trust, Wolverhampton, UK
4Biostatistics and Health Informatics Department, Institute of Psychiatry, Psychology & Neuroscience, King’s College London, London, UK
5King’s Health Economics, Institute of Psychiatry, Psychology & Neuroscience, King’s College London, London, UK
6King’s Clinical Trials Unit, King’s College London, London, UK

*Corresponding author john.strang@kcl.ac.uk

Declared competing interests of authors: John Strang reports grants and others from Martindale Pharma, grants and others from Mundipharma, and grants and others from Braeburn Pharma, outside the submitted work. In addition, John Strang has a Euro-Celtique patent issued, and a King’s College London patent pending. Michael Kelleher reports grants from the National Institute for Health Research (NIHR) during the conduct of the study, others from South London and Maudsley NHS Foundation Trust, Public Health England, Braeburn Pharma and Reckitt Benckiser, personal fees from Mundipharma and non-financial support from Cephaid, outside the submitted work. Sarah Byford reports grants from NIHR Health Technology Assessment programme during the conduct of the study. John Marsden reports investigator-led, educational grant funding from Indivior (administered by Action-on-Addiction) for a study of personalised psychosocial intervention for non-response to opioid agonist treatment. He declares consultancy for the US National Institute on Drug Abuse Centre for Clinical Trials Network. In the past 3 years, he received honoraria from Merck Serono (2015; clinical oncology training), Martindale (2017; expert meeting on opioid use disorder), and Indivior (via PCM Scientific) as co-chairperson (2015, 2016) and chairperson (2017) for the conference on Improving Outcomes in Treatment of Opioid Dependence.

Published January 2019
DOI: 10.3310/hta23030
Scientific summary

The NEAT three-arm RCT
Health Technology Assessment 2019; Vol. 23: No. 3
DOI: 10.3310/hta23030

NIHR Journals Library www.journalslibrary.nihr.ac.uk
Scientific summary

Background

The Naltrexone Enhanced Addiction Treatment (NEAT) trial was for adults with a diagnosis of opioid use disorder (OUD) as defined in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition; the most common OUD being illicit heroin use in the UK setting) in the past year, who are detoxified (zero opioid tolerance) and are voluntarily seeking help to stay away from heroin. The primary purpose of the trial was to evaluate the clinical effectiveness and cost-effectiveness of the enhanced naltrexone relapse prevention therapy programme for the treatment of opioid use disorder following National Institute for Health and Care Excellence (NICE) guidelines [NICE. Drug Misuse: Psychosocial Interventions. Clinical Guideline (CG)51. London: NICE; 2007]. The NEAT trial was designed to evaluate two formulations of this medication: a 90-day implanted, long-acting form and a short-acting oral tablet form (the active comparator).

Objectives

Primary objectives

The aim of the NEAT study was to determine the clinical effectiveness and cost-effectiveness of enhanced naltrexone in the treatment of OUD, with the primary objective of answering the following questions:

1. Is extended-release naltrexone treatment more effective than placebo extended-release naltrexone at reducing heroin use?
2. Is extended-release naltrexone more effective than oral naltrexone at reducing heroin use?
3. What is the relative cost-effectiveness of extended-release naltrexone and oral naltrexone treatment in terms of quality-adjusted life-years?
4. Is extended-release naltrexone more cost-effective than oral naltrexone in terms of quality-adjusted life-years gained?

Objectives 1 and 2 were assessed by urine drug screen (UDS)-verified abstinence from heroin. Objectives 3 and 4 were assessed using health-related quality of life measures.

Secondary objectives

The secondary objectives of NEAT were to:

1. compare treatment retention and medication and psychological intervention adherence rates among the extended-release naltrexone, oral naltrexone and placebo conditions
2. contrast the extended-release naltrexone, oral naltrexone and placebo conditions on quality-of-life indices
3. contrast extended-release naltrexone, oral naltrexone and placebo conditions on:
   - heroin and cocaine craving
   - self-reported opioid, cocaine, amphetamine and benzodiazepine use (with past 48-hour abstinence verified via UDS)
   - alcohol use
   - injection health risk behaviours
   - psychological health (depression and anxiety symptoms)
4. document the safety of extended-release naltrexone and oral naltrexone
5. compare patterns of heroin relapse among the extended-release naltrexone, oral naltrexone and placebo conditions.

Methods

The NEAT trial was a definitive, two-centre, three-arm, parallel group, placebo-controlled, double-blind, double-dummy, Phase III randomised controlled trial. It evaluated and compared the effectiveness of oral naltrexone with implanted extended-release naltrexone as relapse prevention therapy for OUD. After a literature review and discussion with experts, the team selected 12 weeks as an optimum duration over which to deliver medication, the psychological intervention and the incentivised clinical attendance protocol. Primary and secondary outcomes were assessed after 12 weeks, with follow-up interviews after 16, 24 and 36 weeks.

The trial was double blind. Active and placebo oral medication were produced and encapsulated identically. Active and placebo implant devices were produced and packaged identically. Clinicians and research workers completing baseline, clinic attendance assessments and all follow-ups were blind to group allocation, as were patients and pharmacists. This design ensured that the study had a high level of both treatment integrity (delivery of the treatment as intended) and treatment differentiation (treatment conditions differed from one another in the intended manner). The trial had three groups:

- group A – active extended-release naltrexone and placebo oral naltrexone
- group B – placebo extended-release naltrexone and active oral naltrexone
- group C – placebo extended-release naltrexone and placebo oral naltrexone

Results

Six patients were recruited and randomised into the NEAT trial. All patients were recruited from the London site by community referral. Three patients were randomised to double placebo, two patients were randomised to active extended-release naltrexone and oral naltrexone placebo, and one patient was allocated to extended-release naltrexone placebo and active oral naltrexone.

Two patients had no positive UDS samples for heroin during the 12-week treatment period, one patient had only one positive UDS sample and the remaining patients had two, six and eight positive UDS samples for heroin. All patients had at least one non-attendance at the clinic (range 1–14). Three patients self-disclosed using heroin during the 12-week treatment period and three patients reported that they did not use heroin during the treatment period. Four of the patients disclosed having a heroin lapse – three of these were during the 12-week treatment period (at 4–5 weeks from randomisation for all three) and one patient disclosed having a heroin lapse at 16 weeks after randomisation (during the follow-up period). Three patients did not take other substances during the 12-week treatment period and three patients were found to have taken other substances (cocaine, methadone, amphetamines, other opioids and benzodiazepine) during this time. Follow-up data on heroin and other substance use were incomplete at the study close.

Three of the patients reported pain at the site of the implant. One patient reported redness, swelling and pain 1 week after the date of the implant, and pus at the site of the implant 2 weeks after implantation. The second of these patients experienced intermittent burning and pain at the implant site, reported at 2 and 3–4 weeks after implantation, and the implant was reported to be unchanged at 5 weeks after implantation. The third of these patients reported swelling at the implant site 3 weeks after implantation. Three of the patients took all their study medication for the duration of the treatment period. Only one patient and one clinician were able to correctly guess the patient’s treatment allocation (this happened to be for the same patient). No patients withdrew from the trial.
Limitations

It is not possible to reach firm conclusions from the observations on the small number of study participants who entered the study. This is a major limitation within this report. However, further understanding of the obstacles encountered and all elements included in the trial design will become available later from the ongoing qualitative investigation of the knowledge, attitudes and behaviour of the six study participants, or potential study participants, all clinical staff and other key individuals. The double-blind, double-dummy trial design was challenging in terms of arrangements to produce the supply of active and placebo treatments and also in terms of introducing this trial design to a treatment field that had not previously encountered it: however, once established, it was broadly understood and acceptable to many potential study participants as well as to staff. Considerable problems were encountered with the stipulated requirement of a validated ‘detoxified’ status prior to the initiation of the study naltrexone and the requirement for a consent cooling-off period, and also an additional delay awaiting the surgical implant procedure. Ways around these obstacles were developed, to some extent, to mitigate the problems. Difficulty in recruiting study participants on release from prison reduced the ability to apply this treatment to this potentially important patient population.

Conclusions for practice and research

The bolder trial design (double-blind, double-dummy, placebo-controlled) was challenging to prepare and to explain; however, once the implementation stage was reached, there appeared to be satisfactory acceptability to much of the patient population and clinical staff. However, major clinical and research procedural obstacles, alongside major upheaval to the organisation and delivery of treatment services across England, led to extremely poor levels of actual patient entry into the trial.

Implications for future research

It remains important to investigate the potential therapeutic value of the opiate antagonist naltrexone, and to compare the established oral form with the new ultra-long-acting depot implant formulations that have been developed, but for which no licensed products exist in Europe and on which research evidence in real-world clinical settings remains insufficient. Despite the small number of study participants recruited up to the point of the decision to close the NEAT trial, some tentative conclusions can be reached, which are relevant to potential future work. The blinding of the active/placebo medications appeared to be good. Self-report was not sufficient to detect instances of heroin use, although subsequent descriptions of lapse events yielded more data. Self-report plus urine analysis gave a fuller picture. Instances of lapsed heroin use were not necessarily followed by full relapse, and future work should consider the lapse–relapse relationship. Smoother navigation of recruitment, consent and procedures will be required if future trials of the same design are to be implemented. The prison release setting is an area that warrants special consideration for this treatment and could wisely be included in planning for a similar future trial.

Trial registration

This trial is registered as ISRCTN95809946.

Funding

This project was funded by the National Institute for Health Research Health Technology Assessment programme and will be published in full in Health Technology Assessment; Vol. 23, No. 3. See the NIHR Journals Library website for further project information.
Criteria for inclusion in the Health Technology Assessment journal

Reports are published in Health Technology Assessment (HTA) if (1) they have resulted from work for the HTA programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.

Reviews in Health Technology Assessment are termed 'systematic' when the account of the search appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others.

HTA programme

The HTA programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. ‘Health technologies’ are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care.

The journal is indexed in NHS Evidence via its abstracts included in MEDLINE and its Technology Assessment Reports inform National Institute for Health and Care Excellence (NICE) guidance. HTA research is also an important source of evidence for National Screening Committee (NSC) policy decisions.

For more information about the HTA programme please visit the website: http://www.nets.nihr.ac.uk/programmes/hta

This report

The research reported in this issue of the journal was funded by the HTA programme as project number 10/46/01. The contractual start date was in September 2014. The draft report began editorial review in October 2017 and was accepted for publication in May 2018. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors’ report and would like to thank the reviewers for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report.

This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, NETSCC, the PHR programme or the Department of Health and Social Care. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, NETSCC, the PHR programme or the Department of Health and Social Care.

© Queen’s Printer and Controller of HMSO 2019. This work was produced by Strang et al. under the terms of a commissioning contract issued by the Secretary of State for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

Published by the NIHR Journals Library (www.journalslibrary.nihr.ac.uk), produced by Prepress Projects Ltd, Perth, Scotland (www.prepress-projects.co.uk).
NIHR Journals Library Editor-in-Chief

**Professor Ken Stein**  Chair of HTA and EME Editorial Board and Professor of Public Health, University of Exeter Medical School, UK

NIHR Journals Library Editors

**Professor Ken Stein**  Chair of HTA and EME Editorial Board and Professor of Public Health, University of Exeter Medical School, UK

**Professor Andrée Le May**  Chair of NIHR Journals Library Editorial Group (HS&DR, PGfAR, PHR journals)

**Professor Matthias Beck**  Professor of Management, Cork University Business School, Department of Management and Marketing, University College Cork, Ireland

**Dr Tessa Crilly**  Director, Crystal Blue Consulting Ltd, UK

**Dr Eugenia Cronin**  Senior Scientific Advisor, Wessex Institute, UK

**Dr Peter Davidson**  Consultant Advisor, Wessex Institute, University of Southampton, UK

**Ms Tara Lamont**  Scientific Advisor, NETSCC, UK

**Dr Catriona McDaid**  Senior Research Fellow, York Trials Unit, Department of Health Sciences, University of York, UK

**Professor William McGuire**  Professor of Child Health, Hull York Medical School, University of York, UK

**Professor Geoffrey Meads**  Professor of Wellbeing Research, University of Winchester, UK

**Professor John Norrie**  Chair in Medical Statistics, University of Edinburgh, UK

**Professor John Powell**  Consultant Clinical Adviser, National Institute for Health and Care Excellence (NICE), UK

**Professor James Raftery**  Professor of Health Technology Assessment, Wessex Institute, Faculty of Medicine, University of Southampton, UK

**Dr Rob Riemsma**  Reviews Manager, Kleijnen Systematic Reviews Ltd, UK

**Professor Helen Roberts**  Professor of Child Health Research, UCL Great Ormond Street Institute of Child Health, UK

**Professor Jonathan Ross**  Professor of Sexual Health and HIV, University Hospital Birmingham, UK

**Professor Helen Snooks**  Professor of Health Services Research, Institute of Life Science, College of Medicine, Swansea University, UK

**Professor Jim Thornton**  Professor of Obstetrics and Gynaecology, Faculty of Medicine and Health Sciences, University of Nottingham, UK

**Professor Martin Underwood**  Warwick Clinical Trials Unit, Warwick Medical School, University of Warwick, UK

Please visit the website for a list of editors: www.journalslibrary.nihr.ac.uk/about/editors

**Editorial contact:** journals.library@nihr.ac.uk